Cancer, a complex group of diseases characterized by uncontrolled cell proliferation, remains a significant global health challenge.  While traditional cancer treatments have shown efficacy, significant limitations persist, primarily due to inter-patient heterogeneity in response. Recent breakthroughs in understanding the genetic basis of cancer have ushered in the era of personalized medicine, offering the promise of tailored therapies based on an individual's unique tumor profile. This research paper explores the advancements driving this paradigm shift, focusing on the identification of driver mutations, the development of targeted therapies, and the integration of genomic data into clinical practice.  Significant progress has been made in next-generation sequencing (NGS) technologies, enabling rapid and cost-effective profiling of entire genomes and transcriptomes.  This high-throughput data allows for the identification of specific oncogenic mutations, facilitating the selection of targeted therapies like tyrosine kinase inhibitors (TKIs) and immunotherapy agents.  Furthermore, the integration of bioinformatics and machine learning techniques is enhancing the prediction of treatment response and the identification of novel therapeutic targets.  However, challenges remain, including the cost and accessibility of genomic testing, the development of robust predictive biomarkers, and the ethical considerations associated with personalized cancer care. This paper will critically evaluate these advancements and their implications for the future of cancer treatment.